首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Crystal Structure and Pharmacological Characterization of a Novel N-Methyl-d-aspartate (NMDA) Receptor Antagonist at the GluN1 Glycine Binding Site
【2h】

Crystal Structure and Pharmacological Characterization of a Novel N-Methyl-d-aspartate (NMDA) Receptor Antagonist at the GluN1 Glycine Binding Site

机译:新型N-甲基-d-天冬氨酸(NMDA)受体拮抗剂在GluN1甘氨酸结合位点的晶体结构和药理特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

NMDA receptors are ligand-gated ion channels that mediate excitatory neurotransmission in the brain. They are tetrameric complexes composed of glycine-binding GluN1 and GluN3 subunits together with glutamate-binding GluN2 subunits. Subunit-selective antagonists that discriminate between the glycine sites of GluN1 and GluN3 subunits would be valuable pharmacological tools for studies on the function and physiological roles of NMDA receptor subtypes. In a virtual screening for antagonists that exploit differences in the orthosteric binding site of GluN1 and GluN3 subunits, we identified a novel glycine site antagonist, 1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one (TK40). Here, we show by Schild analysis that TK40 is a potent competitive antagonist with Kb values of 21–63 nm at the GluN1 glycine-binding site of the four recombinant GluN1/N2A-D receptors. In addition, TK40 displayed >100-fold selectivity for GluN1/N2 NMDA receptors over GluN3A- and GluN3B-containing NMDA receptors and no appreciable effects at AMPA receptors. Binding experiments on rat brain membranes and the purified GluN1 ligand-binding domain using glycine site GluN1 radioligands further confirmed the competitive interaction and high potency. To delineate the binding mechanism, we have solved the crystal structure of the GluN1 ligand-binding domain in complex with TK40 and show that TK40 binds to the orthosteric binding site of the GluN1 subunit with a binding mode that was also predicted by virtual screening. Furthermore, the structure reveals that the imino acetamido group of TK40 acts as an α-amino acid bioisostere, which could be of importance in bioisosteric replacement strategies for future ligand design.
机译:NMDA受体是介导大脑中兴奋性神经传递的配体门控离子通道。它们是由结合甘氨酸的GluN1和GluN3亚基以及结合谷氨酸的GluN2亚基组成的四聚体复合物。区分GluN1和GluN3亚基的甘氨酸位点的亚基选择性拮抗剂将是研究NMDA受体亚型的功能和生理作用的有价值的药理工具。在对利用GluN1和GluN3亚基正构结合位点差异的拮抗剂进行的虚拟筛选中,我们鉴定了一种新型的甘氨酸位点拮抗剂1-thioxo-1,2-dihydro- [1,2,4] triazolo [4,3 -a]喹喔啉-4(5H)-1(TK40)。在这里,我们通过Schild分析表明,TK40是一种有效的竞争性拮抗剂,在四个重组GluN1 / N2A-D受体的GluN1甘氨酸结合位点的Kb值为21-63 nm。此外,相对于含有GluN3A和GluN3B的NMDA受体,TK40对GluN1 / N2 NMDA受体的选择性高100倍以上,而对AMPA受体没有明显影响。使用甘氨酸位点GluN1放射性配体在大鼠脑膜和纯化的GluN1配体结合域上的结合实验进一步证实了竞争相互作用和高效力。为了描述结合机制,我们已经解决了与TK40复合的GluN1配体结合域的晶体结构,并显示TK40以同样通过虚拟筛选预测的结合模式结合到GluN1亚基的正构结合位点。此外,该结构表明,TK40的亚氨基乙酰氨基基团起着α-氨基酸生物等排体的作用,这在未来等位体设计的生物等排替代策略中可能很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号